ES2104731T3 - Micobacterium utilizado como adyuvante para antigenos. - Google Patents

Micobacterium utilizado como adyuvante para antigenos.

Info

Publication number
ES2104731T3
ES2104731T3 ES91919563T ES91919563T ES2104731T3 ES 2104731 T3 ES2104731 T3 ES 2104731T3 ES 91919563 T ES91919563 T ES 91919563T ES 91919563 T ES91919563 T ES 91919563T ES 2104731 T3 ES2104731 T3 ES 2104731T3
Authority
ES
Spain
Prior art keywords
antigens
micobacterium
adjuvant
micobacteria
immunoregulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919563T
Other languages
English (en)
Inventor
Graham Arthur William Old Rook
John Stanford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909024282A external-priority patent/GB9024282D0/en
Priority claimed from GB919115410A external-priority patent/GB9115410D0/en
Application filed by University College London filed Critical University College London
Application granted granted Critical
Publication of ES2104731T3 publication Critical patent/ES2104731T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EL METERIAL INMUNOREGULADOR DE UNA MICOBACTERIA DIFERENTE A LA "M. TUBERCULOSIS", ESPECIALMENTE CELULAS MUERTAS DE "M.VACCAE", ES UN COADYUDANTE VENTAJOSOS PARA SU ADMINISTRACION CON ANTIGENOS (INCLUIDOS ALERGENOS).
ES91919563T 1990-11-08 1991-11-08 Micobacterium utilizado como adyuvante para antigenos. Expired - Lifetime ES2104731T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909024282A GB9024282D0 (en) 1990-11-08 1990-11-08 Antigen carrier
GB919115410A GB9115410D0 (en) 1991-07-17 1991-07-17 Antigen carrier

Publications (1)

Publication Number Publication Date
ES2104731T3 true ES2104731T3 (es) 1997-10-16

Family

ID=26297923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919563T Expired - Lifetime ES2104731T3 (es) 1990-11-08 1991-11-08 Micobacterium utilizado como adyuvante para antigenos.

Country Status (11)

Country Link
US (1) US5599545A (es)
EP (1) EP0556248B1 (es)
JP (1) JPH06501479A (es)
AT (1) ATE154759T1 (es)
AU (1) AU660430B2 (es)
CA (1) CA2095855C (es)
DE (1) DE69126668T2 (es)
DK (1) DK0556248T3 (es)
ES (1) ES2104731T3 (es)
GR (1) GR3024750T3 (es)
WO (1) WO1992008488A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
WO1994016727A1 (en) * 1993-01-29 1994-08-04 Vetrepharm, Inc. Immunotherapeutic composition
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5725860A (en) * 1994-03-07 1998-03-10 Auckland Uniservices Limited Method for reducing the risk of developing diabetes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU730548B2 (en) * 1996-12-18 2001-03-08 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the TH2 activity of the immune system
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
AU6780498A (en) * 1997-03-28 1998-10-22 Cytoclonal Pharmaceutics, Inc. Mycobacterium recombinant vaccines
WO1998047520A1 (en) * 1997-04-24 1998-10-29 Lovelace Respiratory Research Institute Prevention and treatment of allergic disease by targeted development of protective t-helper lymphocyte immunity
KR20060111731A (ko) 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
CZ20002669A3 (cs) * 1998-01-23 2001-11-14 National Jewish Medical And Research Center Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
JP4768122B2 (ja) 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
JP4415200B2 (ja) * 1999-01-29 2010-02-17 大塚製薬株式会社 遅発育性抗酸菌ポリペプチド
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20040247622A1 (en) * 1999-06-02 2004-12-09 Genesis Research And Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
JP2003519668A (ja) 2000-01-14 2003-06-24 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ 熱ショックタンパク質融合タンパク質による、ｃｄ４＋ｔ細胞非依存性のインビボｃｔｌ惹起による個別ａｔｐ結合ドメインのマッピング
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
DK1296711T3 (da) 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
GB0025694D0 (en) * 2000-10-19 2000-12-06 Univ London Vaccine
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
HK1079705A1 (zh) 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
EP1549135A4 (en) * 2002-09-20 2006-01-11 Us Agriculture VACCINE COMPOSITIONS AND AUXILIARY
CA2620943A1 (en) * 2005-09-02 2007-03-08 Iomai Corporation Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
KR20180015269A (ko) 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (es) * 1971-11-19 1975-02-07 Anvar
NL7308450A (es) * 1972-06-20 1973-12-27
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4930169A (en) * 1988-12-27 1990-06-05 Kenneth Davison Apparatus for patient hydrotherapy and manipulative treatment by a therapist
DK0454735T3 (da) * 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
DE69126668D1 (de) 1997-07-31
GR3024750T3 (en) 1997-12-31
CA2095855C (en) 2003-04-29
JPH06501479A (ja) 1994-02-17
CA2095855A1 (en) 1992-05-09
DE69126668T2 (de) 1997-10-23
EP0556248A1 (en) 1993-08-25
US5599545A (en) 1997-02-04
DK0556248T3 (da) 1997-10-27
AU660430B2 (en) 1995-06-29
ATE154759T1 (de) 1997-07-15
EP0556248B1 (en) 1997-06-25
WO1992008488A1 (en) 1992-05-29
AU8874191A (en) 1992-06-11

Similar Documents

Publication Publication Date Title
ES2104731T3 (es) Micobacterium utilizado como adyuvante para antigenos.
NO922566L (no) Implantasjonsmateriale som gir naer vaskularisering
ES2080739T3 (es) Nitro-compuestos insecticidamente activos.
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
SE8406538D0 (sv) Novel derivatives of purine
DE3681145D1 (de) Immunstimulierende mittel.
ES555005A0 (es) Un procedimiento para preparar una formulacion en emulsion de anfotericina b adecuada para administracion parenteral.
ES2098358T3 (es) Metodo para preparar cristales de interferon alfa-2.
ES8607020A1 (es) Acidos 1-ciclopropilquinolon-3-carboxilicos
ES2104131T3 (es) Mycobacterium vaccae utilizado en el tratamiento de afecciones auto-inmunes de larga duracion.
ES2189788T3 (es) Regulacion de las respuestas del sistema inmunitario utilizando citoquinas y antigenos.
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
NO930203L (no) Polypeptidforbindelser med veksthormonfrigjoerende aktivitet
ES458197A1 (es) Un procedimiento para la preparacion de nuevos peptidoglica-nos.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES2088431T3 (es) Preparacion biologica y su utilizacion.
DK23490A (da) Implanteret antibiotisk tilberedning med reguleret frigivelse
IT1251838B (it) Uso della nimesulide nel trattamento della cataratta
ES2103575T3 (es) Procedimiento para la preparacion de 9-(2-hidroxi)-etoximetil-guanina.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556248

Country of ref document: ES